Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
25% of Chronic Pain Patients Show ADHD Traits
A University of Tokyo study of 958 Japanese adults with chronic pain found that roughly 25% exhibited significant ADHD traits, a rate 2.4 times higher than in the general population. The research shows that ADHD does not directly cause pain but amplifies it through heightened anxiety, depression, and catastrophizing. Patients with both conditions often fail to respond to standard analgesic protocols, suggesting that untreated ADHD may undermine pain management. The authors recommend routine ADHD screening in pain clinics and a multimodal treatment plan that blends medication, cognitive‑behavioral therapy, and rehabilitation.
New ADC Yields Encouraging Clinical Benefit in Platinum-Resistant Ovarian Cancer
In a Phase I trial presented at AACR 2026, the investigational antibody‑drug conjugate QLS5132 demonstrated notable antitumor activity in patients with advanced platinum‑resistant ovarian cancer. Among 28 heavily pretreated participants, the overall objective response rate was 50% and disease control...
STAT+: Sanofi Research Priorities in Flux as New CEO Logs In
Sanofi’s new chief executive, Belén Garijo, assumes leadership amid questions about the French drugmaker’s research direction. The company recently intensified its immunology portfolio, but recent trial disappointments have dampened expectations. Garijo is expected to reassess R&D allocations, potentially shifting focus...
Senate Hearings Put RFK Jr.'s Vaccine Stance Under Fire as Cassidy Questions HHS Secretary
Health Secretary Robert F. Kennedy Jr. faced two Senate hearings chaired by Sen. Bill Cassidy, where he denied anti‑vaccine claims and defended a $1 billion NIH vaccine research push. Cassidy, a physician‑senator battling a Trump‑backed primary challenger, pressed Kennedy on vaccine...
Roche, Facing Biosimilar Threats, Puts Faith in New Cancer and Obesity Drugs
Roche said its emerging breast‑cancer pill giredestrant and a suite of obesity drugs could generate up to $9 billion in peak annual sales. First‑quarter sales rose 6% to 14.7 billion Swiss francs (≈$18.8 billion) but fell 5% on currency effects, and the company...
Molina Controls Costs in Q1 but Future Medicaid Spending in Doubt
Molina Health Care posted a $14 million Q1 profit, beating analyst forecasts, while its medical loss ratios improved to 92% in Medicaid and 89.9% in Medicare Advantage. The gains were offset by a 2% drop in overall membership, driven by stricter...
Feeling Stuck with MCAS because of Finances? Here’s What You Need to Know.
A recent MC360 survey revealed finances and lack of knowledgeable help as the top barriers for people with mast cell activation syndrome (MCAS). To address this, the MC360 Clinic rolled out three tiered services: a $299 Strategy Session, a $499...
Is This The Part Of Endometriosis Treatment We’ve Been Missing?
Endometriosis affects over 10% of women, yet pain severity often mismatches visible lesions. A Washington State University study led by Kanako Hayashi shows repeated menstrual cycles trigger neuroinflammation, sensitizing the brain’s pain pathways so pain persists even after lesion removal....
90% of Chinese Trial Participants Hear Better After Gene Therapy for Deafness
A Chinese clinical trial of an experimental gene therapy for congenital deafness reported that 90% of participants experienced significant hearing improvement, including whispers and normal conversation. The results, published in Nature, mark the most compelling early evidence for a potential...
Researchers Use Multi-Modality Imaging to Learn More About MINOCA
Researchers at NYU Langone Health used combined optical coherence tomography and cardiac MRI to uncover the underlying causes of myocardial infarction with nonobstructive coronary arteries (MINOCA) in a large mixed‑sex cohort. The multi‑modality approach identified a definitive cause in 79%...
Biossil Exits Stealth with $70 Million USD to Give Failed Medicines a Second Chance
Toronto‑based biotech Biossil has emerged from stealth after raising roughly $70 million in equity from investors including OpenAI and Founders Fund. The company leverages an AI platform to spot abandoned drug candidates, then licenses or purchases them to fast‑track development. It...
Almanac Health Launches with $10M to Scale Research-Validated Clinical AI for Point-of-Care Support
Almanac Health announced a $10 million seed round, bringing total funding to nearly $12 million, led by F‑Prime with participation from General Catalyst and Lightspeed Venture Partners. Founded by Stanford physician‑researcher Cyril Zakka, the company commercializes a retrieval‑augmented generation (RAG) system that...
Department of Justice Officially Reschedules Marijuana: What Truckers Need to Know
The U.S. Department of Justice officially moved state‑licensed marijuana from Schedule I to Schedule III, allowing only FDA‑approved products and those tied to state medical licenses to benefit. The change acknowledges medical value but does not legalize cannabis federally and leaves commercial...
Doctors Must Speak Up or Lose Public Influence
Brutal truth: MD/MS doctors are losing the internet to people with weekend certifications. You studied for 10–15 years. They studied lighting, scripting, and delivery. They talk confidently about gut health, hormones, heart, brain. You hv depth. They hv reach. Hot take: The biggest threat to MD/MS doctors...
NeuFluent Expands Innovation Ecosystem with New Intelligent Implants and Robotics Initiative
NeuFluent, a neuroscience venture studio, announced an "intelligent implants and robotics" initiative, expanding its portfolio beyond brain‑computer interfaces and AI‑driven drug development. The program is headed by Dr. Kevin Foley, a pioneer of minimally invasive spinal surgery and robotics, who...
Voices: Freda Mowad, M.S., CCC-SLP, Chief Strategy Officer, Focal Point Care
Focal Point Care, launched a year ago, consolidates three specialized firms—Guided Care (managed‑care contracting), QRM (in‑house rehab management) and Future Care Consultants (billing and back‑office services)—to offer skilled‑nursing operators a single source for clinical, operational and financial support. The integrated...
Do Older Adults Need Routine Colonoscopies Or Low Thyroid Drugs?
A new JAMA analysis of 90,000 veterans shows that routine colonoscopies after age 75 yield minimal cancer‑prevention benefit, with incidence under 1% and mortality differences negligible. A separate Dutch study of 360 seniors found that two‑thirds of patients on low‑dose...
Backed by Redesign Health, Gravity Rail Launches with $2.75M to Provide No-Code AI Operating System for Healthcare
Gravity Rail, backed by Redesign Health, launched with a $2.75 million seed round. The no‑code AI operating system lets healthcare teams build, certify, and run AI engagement workflows across voice, SMS, email and web without programming. Early adopters reported a 30%...
Drug Trials Snapshot: NUZOLVENCE
Entasis Therapeutics received FDA approval on Dec 12 2025 for NUZOLVENCE, a single‑dose oral granule treatment for uncomplicated urogenital gonorrhea in patients aged 12 and older. The approval is based on a phase 3, open‑label, non‑inferiority trial of 930 participants across five countries,...
FDA Approves 2 Implantable Heart Devices From Biotronik
The FDA has cleared Biotronik’s Acticor Sky and Rivacor Sky implantable cardioverter‑defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT‑D) systems, set to launch at the Heart Rhythm Society 2026 meeting. The devices introduce left bundle branch area pacing, single‑lead DX atrial sensing,...
Stäubli Launches TX2-60L MedX Ready Medical Robot
Stäubli Robotics unveiled the TX2‑60L MedX Ready, a compact six‑axis robot built for surgical and medical applications. The system features MedXguiding, an intuitive manual guidance interface, and is produced under an ISO 13485‑certified quality management system. Stäubli highlights its extensive validation...
GE HealthCare: First Patient Dosed in Trial for Manganese-Based MRI Contrast Agent
GE HealthCare announced that the first patient was dosed in the international Phase 2/3 LUMINA trial of its manganese‑based MRI contrast agent, mangaciclanol, at the Mayo Clinic. The agent has earned FDA Fast Track designation for adults and children aged two...
The NHS Cannot Solve Women’s Health Inequalities Alone
The UK government’s renewed Women’s Health Strategy promises to add a decade to healthy life expectancy in deprived areas and curb medical misogyny, but it largely ignores the social determinants that drive health outcomes. Evidence shows women are disproportionately affected...
The Agentforce Life Sciences Consultant Certification
Salesforce introduced the Certified Agentforce Life Sciences Consultant exam, a Spring ’26‑aligned credential that validates expertise in building AI‑driven, compliant solutions for pharma, biotech and MedTech firms. The 60‑question, 105‑minute test costs $200 (≈¥30,000) and requires a 62% passing score,...
Sanofi Posts Upbeat Sales as R&D Pressure Builds
Sanofi reported first‑quarter net sales of €10.5 billion (about $12.3 billion), a 6.2% rise that beat Wall Street forecasts, driven largely by a 31% jump in Dupixent revenue. The French group reaffirmed its 2026 outlook, expecting high‑single‑digit sales growth and earnings that...
In Pakistan’s Deadly Heat, Low-Cost Cooling Tools Offer a Lifeline for Pregnant Women
Researchers at Aga Khan University tested low‑cost cooling tools—canvas canopies, hand fans, damp cloths and reflective paint—in Karachi’s hottest districts. The interventions lowered indoor temperatures by 3‑4 °C (5‑7 °F), offering relief where electricity for AC or fans is unreliable. Pregnant women...
Tech Giants Converge on AI‑Biology at SynBioBeta 2026
Silicon Valley's biggest tech players aren't just watching synthetic biology from a distance. They're showing up in person. This year at @SynBioBeta 2026, delegations from @Amazon, @Google, @Apple, @OpenAI, @Anthropic, @NVIDIA, and others are coming to San Jose to see what's...
Zotatifin
Effector Therapeutics and Switzerland’s SJP Biotec have entered Phase 2 trials of zotatifin, an intravenous eIF4A inhibitor, in selected advanced solid tumors. The study targets cancers such as breast, lung and pancreatic that rely heavily on dysregulated protein translation. Early Phase 1...
FTC Order in TruHeight Case Signals Scrutiny of Height Claims and Incentivized Reviews
The FTC issued an administrative order against TruHeight, finding its height‑increase claims for children unsubstantiated and its review practices deceptive. The agency required the company to back any health claims with competent, double‑blind clinical evidence and to stop incentivizing 5‑star...
Trump Administration Eases Rules on some Marijuana Categories. Here's What to Know
The Trump administration announced that medical marijuana will be moved from Schedule I to Schedule III, placing it alongside substances such as codeine. The change applies only to FDA‑approved products and those sold under state medical licenses, leaving recreational cannabis untouched. By...
The Godmother of Silicon Valley Is Helping Launch an AI Healthcare Residency Program
Esther Wojcicki, dubbed the "Godmother of Silicon Valley," is spearheading an AI healthcare residency program aimed at equipping startup co‑founders with the technical and clinical skills needed to launch successful digital health ventures. The twelve‑month curriculum pairs entrepreneurs with seasoned...
Trump Administration Moves to Speed up Medicare Coverage for Breakthrough Cardiology Devices
U.S. CMS and FDA have unveiled the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway, a joint proposal to accelerate Medicare coverage for FDA‑designated breakthrough devices. Under RAPID, a device’s full FDA approval would trigger a 30‑day public comment...
Prior Authorization: Care, Delayed | EP 3
In this episode of Healthcare Uncovered, hosts Joe Rotino and Wendell Potter expose how prior authorization has become a pervasive barrier that delays critical care, inflates administrative costs, and contributes to patient harm, illustrated by the tragic death of a...
Kurma Partners Closes €215 Million Biofund IV to Back European BioTech Ventures From Paris
Kurma Partners announced the final close of Biofund IV at €215 million (about $232 million), a 35% increase over its €160 million (≈$173 million) predecessor. The fund, backed by pharmaceutical giant CSL, the European Investment Fund and Bpifrance, aims to make roughly twenty investments in...
The COVID Amnesia Project III: The Plot to Erase Who Ordered Lockdowns in 2020
The third installment of the COVID Amnesia Project (CAP) argues that prominent COVID‑19 pundits, especially Dr. Jay Bhattacharya, are rewriting history to hide who actually ordered the 2020 lockdowns. The piece highlights that President Donald Trump and Florida Governor Ron DeSantis were...
NYC Hospital Takes Additional Ambulances Out of Service Due to Financial Challenges
Richmond University Medical Center will retire two 911‑responding ambulances in July, cutting its fleet to four daytime units after ending an overnight shift earlier this year. The reduction reflects the hospital’s financial strain as an independent provider lacking the scale...
5 Underinvested Areas in Sleep Health That Healthtech Startups Are Finally Addressing
Most Americans suffer poor sleep, yet mainstream products remain limited to melatonin gummies, foam mattresses and CPAP machines. Healthtech startups are now targeting five under‑invested segments—perimenopausal hormonal sleep, shift‑worker circadian care, grounding and nervous‑system regulation, pediatric sleep beyond apnea, and...
Implant Keeps Drug‑Producing Cells Alive for a Month
A new bioelectronic implant can support populations of three different drug-producing cells for more than a month, keeping them supplied with the correct amounts of oxygen. These cells could produce drugs to treat various cancers, autoimmune diseases like arthritis, and...
GenAI Enables Asking Right Questions, Not More Dashboards
In healthcare, we never really had a data problem. And honestly, the same is true in most industries I’ve worked in. There was 𝗯𝗹𝗲𝗻𝘁𝘆 𝗼𝗳 𝗱𝗮𝘁𝗮. Usually too much of it. 📊 Claims data. Operational data. Financial data. Customer data. Supply chain data. Workflow data. The real problem was...
Novo's Pill for Kids; Altimmune’s $225M Offering; Merck Teams with Google Cloud
Novo Nordisk reported that its oral GLP‑1 drug Rybelsus reduced hemoglobin A1C by 0.83% in adolescents aged 10‑17 with type‑2 diabetes after about six months of treatment. The result marks the first pediatric efficacy data for a GLP‑1 pill, expanding...
Roche Bets on Cancer and Obesity Drugs Amid Biosimilar Pressure
Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs https://t.co/IIt0INA9sI @ByJonGardner $RHHBY
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/n2tSuJXS5b
Is the Vitamin K Shot Necessary for Newborns?
The vitamin K injection given at birth remains the standard defense against a rare but potentially fatal bleeding disorder in newborns. Between 2017 and 2024, parental refusal of the shot grew from 3% to over 5%, driven by broader medical mistrust...
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/VPIH8iphVP
Phase 3 Trial Tests Daratumumab Reg
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/xv1RlCv8gl
Modern Healthcare Is Data‑rich but Insight‑poor
Healthcare now produces unprecedented volumes of real‑world data from EHRs, devices, claims and registries, yet this abundance has not yielded better patient outcomes. The author argues the gap stems from evidence that remains fragmented, retrospective and geared toward compliance rather...
Sanofi Reports Strong Sales Amid Growing R&D Pressure
Sanofi posts upbeat sales as R&D pressure builds https://t.co/4WUccjXY5D by Kristin Jensen $SNY + 2% $REGN
Amazon Teams with Grow Therapy for Employee Mental Health
Whoa... The employer behavioral health wars are heating up! Amazon is partnering with Grow Therapy on EAP. 👇 https://t.co/jVDA2xBhsE
AI Becomes Healthcare’s Operating Layer, EHR Becomes Plumbing
This is bigger than 𝗰𝗼𝗽𝗶𝗹𝗼𝘁𝘀. 🚀 OpenAI, Anthropic, and Google are racing to become the 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗹𝗮𝘆𝗲𝗿 above healthcare’s fragmented mess. 🏥 Once AI becomes the interface, the EHR stops being the 𝗱𝗲𝘀𝘁𝗶𝗻𝗮𝘁𝗶𝗼𝗻. 📍 It becomes the 𝗽𝗹𝘂𝗺𝗯𝗶𝗻𝗴. 💧
Gene Therapy Cures Specific Deafness—A Modern Miracle
Another modern miracle: Gene therapy cures a form of deafness. Harvard to USA: You're welcome. https://t.co/mfEzVMGugp